Frontline Healthcare Partners, a private equity firm, made a recapitalization and growth investment in Scottsdale, Ariz.-based LivWell Infusions.
LivWell administers highly accessible infusions and injections for patients suffering from compromised immune systems, infectious diseases, and other medical conditions and operates in five states.
Derek Spence, a partner at Frontline, said in an Aug. 16 news release from the firm that backing young companies is a proactive way to improve the quality, accessibility and cost of healthcare.
"LivWell delivers a patient-centric experience while being relentlessly focused on comprehensive support for physician partners. LivWell's unique business model solves pain points for patients and providers and aligns completely with our strategy and approach of partnering with distributed healthcare companies," Mr. Spence said.
The infusion services market is estimated to be more than $100 billion. More than 50 percent of infusions are administered within the hospital setting, where costs can be three to five times higher than similar treatments delivered in outpatient settings, according to the news release.